Cost effectiveness of influenza vaccination in older adults: A critical review of economic evaluations for the 50- to 64-year age group

PharmacoEconomics

Volumn 27, Issue 6, 2009, Pages 439-450

  Newall, Anthony T ^a,b   Kelly, Heath ^c,d   Harsley, Stuart ^e   Scuffham, Paul A ^f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e CSL Biotherapies   (Australia)

^f GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ABSENTEEISM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GROUPS BY AGE; HEALTH CARE COST; HEALTH PROGRAM; HERD IMMUNITY; HOSPITALIZATION COST; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LIFE EXPECTANCY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

AGE FACTORS; COST-BENEFIT ANALYSIS; FORECASTING; HEALTH CARE COSTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LIFE EXPECTANCY; META-ANALYSIS AS TOPIC; MIDDLE AGED; MODELS, ECONOMIC; QUALITY OF LIFE; TREATMENT OUTCOME; VACCINATION;

EID: 68349106703     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200927060-00001     Document Type: Review

References (40)

1. Li CK, Choi BC, Wong TW. Influenza-related deaths and hospitalizations in Hong Kong: a subtropical area. Public Health 2006; 120 (6): 517-524
2. Newall AT, Wood JG, Macintyre CR. Influenza-related hospitalisation and death in Australians aged 50 years and older. Vaccine 2008; 26 (17): 2135-2141
3. Thompson W, Shay D, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-186 (Pubitemid 36068705)
4. Thompson WW, Shay DK, Weintraub E, et al. Influenzaassociated hospitalizations in the United States. JAMA 2004; 292 (11): 1333-1340
5. Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137 (4): 225-231 (Pubitemid 34898552)
6. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161 (5): 749-759
7. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21 (17-18): 2207-2217
8. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118 (1): 68-77 (Pubitemid 40082461)
9. Wood SC, Nguyen VH, Schmidt C. Economic evaluations of influenza vaccination in healthy working-age adults: employer and society perspective. Pharmacoeconomics 2000; 18 (2): 173-183 (Pubitemid 30624900)
10. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
11. Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14 (2): 171-189
12. Australian Institute of Health and Welfare. 2004 adult vaccination survey: summary results. Canberra: AIHW & DoHA, 2005. Report no.: PHE 56
13. Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008; 8 (1): 272
14. Bridges CB, Winquist AG, Fukuda K, et al. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2000; 49 (RR-3): 1-38.
15. Pitman RJ,Melegaro A, Gelb D, et al. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007; 54 (6): 530-538 (Pubitemid 46731221)
16. Aballea S, Chancellor J, Martin M, et al. The costeffectiveness of influenza vaccination for people aged 50 to 64 years: an international model. ValueHealth 2007; 10 (2): 98-116 (Pubitemid 46481137)
17. Aballea S, De Juanes JR, Barbieri M, et al. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain. Vaccine 2007; 25 (39-40): 6900-6910 (Pubitemid 47391104)
18. Maciosek MV, Solberg LI, Coffield AB, et al. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.AmJ Prev Med 2006; 31 (1): 72-79
19. Newall AT, Scuffham PA, Kelly H, et al. The costeffectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia. Vaccine 2008; 26 (17): 2142-2153
20. Prosser LA, O'Brien MA, Molinari NA, et al. Nontraditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics 2008; 26 (2): 163-178
21. Turner DA, Wailoo AJ, Cooper NJ, et al. The costeffectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 2006; 24 (7): 1035-1043 (Pubitemid 43185322)
22. Lopez L, Huang QS. Influenza in New Zealand 2008. Porirua: Institute of Environmental Science and Research (ESR); 2009 [online].Available fromURL: http://www.surv. esr.cri.nz/virology/influenza-annual-report.php [Accessed 2009 Jun 15]
23. Newall AT, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7 (4): 289-296 (Pubitemid 46414076)
24. Beutels P, Scuffham PA, MacIntyre CM. Funding of drugs: do vaccines warrant a different approach. Lancet Infect Dis 2008; 8: 727-733
25. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999; 5 (5): 659-671 (Pubitemid 29493768)
26. Demicheli V, Rivetti D, Deeks JJ, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004; (3): CD00126
27. Demicheli V, Rivetti D, Deeks JJ, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2001; (4): CD001269
28. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123 (7): 518-527
29. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21 (16): 1769-1775
30. Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; (2): CD001269 (Pubitemid 351805943)
31. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980; 112 (6): 798-811
32. Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7 (10): 658-666 (Pubitemid 47444564)
33. Kelly H, Newall AT. Mortality benefits of influenza vaccination in elderly people. Lancet Infect Dis 2008; 8 (8): 462-463 (Pubitemid 352001408)
34. Maciosek MV, Coffield AB, Edwards NM, et al. Methods for prioritizing clinical preventive services: technical report prepared for the National Commission on Prevention Priorities. Minneapolis (MN): HealthPartners Research Foundation, 2006.
35. Prior G. Self-reported health: health survey for England '96. London: The Stationery Office, 1998
36. Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health 2005; 29 (2): 136-142 (Pubitemid 40585235)
37. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25 (27): 5086-5096
38. Grosse SD. Prevention effectiveness: a guide to decision analysis and economic evaluation [appendix I: productivity loss tables]. 2nd ed. New York: Oxford University Press, 2003
39. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002; 20 (19-20): 2562-2578
40. Scuffham PA, Whitty JA, Mitchell AM, et al. The use of QALY weights for QALY calculations. Pharmacoeconomics 2008; 26 (4): 297-310